Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | PAM | P19021 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | CETP | P11597 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28510969 | 0.98 | ALDH1A1 (0.49) | CYP19A1ALDH1A1L3MBTL1MAPK1PAM | |
| SCHEMBL27682051 | 0.94 | CYP19A1 (0.46) | CYP19A1ALDH1A1L3MBTL1MAPK1PAM | |
| SCHEMBL4682195 | 0.91 | ALDH1A1 (0.52) | CYP19A1ALDH1A1L3MBTL1MAPK1PAM | |
| SCHEMBL27655982 | 0.88 | SRD5A2 (0.48) | CYP19A1EPHX2FAAH | |
| SCHEMBL27675998 | 0.87 | CYP19A1 (0.43) | CYP19A1ALDH1A1L3MBTL1MAPK1ADRB2 | |
| SCHEMBL27676012 | 0.85 | FAAH (0.46) | ALDH1A1SMN1; SMN2FAAHCETP | |
| SCHEMBL5729921 | 0.82 | EPHX2 (0.49) | CYP19A1ALDH1A1EPHX2MEN1KMT2A | |
| SCHEMBL27681878 | 0.82 | CYP19A1 (0.41) | CYP19A1ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL27675987 | 0.79 | MEN1 (0.52) | ALDH1A1L3MBTL1HTTSMN1; SMN2MEN1 | |
| SCHEMBL28668672 | 0.79 | TDP1 (0.54) | ALDH1A1MAPK1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115216168-A | Ultraviolet-curable coating composition | 株式会社KCC | 2022-10-21 | — | — | CN | disclosed |
| CN-110621746-B | Ultraviolet-curable coating composition | 株式会社KCC | 2021-09-21 | — | — | CN | disclosed |
| EP-1546098-B1 | 3,6-DISUBSTITUTED AZABICYCLO [3.1.0]HEXANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LAB LTD (IN) | 2008-05-28 | — | — | EP | disclosed |
| US-7265147-B2 | 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2007-09-04 | — | — | US | disclosed |
| EP-1546098-A4 | 3,6-DISUBSTITUTED AZABICYCLO ¬3.1.0|HEXANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LAB LTD (IN) | 2006-08-23 | — | — | EP | disclosed |
| US-20060122253-A1 | 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2006-06-08 | — | — | US | disclosed |
| EP-1546098-A1 | 3,6-DISUBSTITUTED AZABICYCLO [3.1.0]HEXANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004014853-A1 | 3,6-DISUBSTITUTED AZABICYCLO [3.1.0]HEXANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122253-A1 | 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | CYP19A1 1466/4885ALDH1A1 738/4885L3MBTL1 3844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.